cists must verify that both the prescriber and the patient presenting a prescription are enrolled in the Exalgo Alliance and that they are adhering to program requirements, including safe-use conditions being followed by the patient.Upon FDA approval of Exalgo, implementation of the REMS and program monitoring will be handled by Covidien.